Mildronate treatment alters γ-butyrobetaine and l -carnitine concentrations in healthy volunteers

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 9, 2011, Pages 1195-1201

  Liepinsh, Edgars ^a   Konrade, Ilze ^b   Skapare, Elina ^a,b   Pugovics, Osvalds ^a   Grinberga, Solveiga ^a   Kuka, Janis ^a   Kalvinsh, Ivars ^a   Dambrova, Maija ^a  

^a LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

^b RIGA STRADINS UNIVERSITY   (Latvia)

Author keywords

(gamma) butyrobetaine; l carnitine; mildronate; UPLC MS MS

Indexed keywords

CARNITINE; GAMMA BUTYROBETAINE; MILDRONATE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TARGETING; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; LONG TERM CARE; MALE; MEAT; NORMAL HUMAN; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS; URINE LEVEL;

ADULT; BETAINE; CARDIOVASCULAR AGENTS; CARNITINE; DIET; FEMALE; HUMANS; MALE; MEAT; METHYLHYDRAZINES; MIDDLE AGED; YOUNG ADULT;

EID: 80051702880     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01325.x     Document Type: Article

References (33)

1. Simkhovich BZ, et al,. 3-(2,2,2-Trimethylhydrazinium)propionate (THP)-a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol 1988; 37: 195-202.
2. Kuwajima M, et al,. Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. J Pharmacol Exp Ther 1999; 289: 93-102. (Pubitemid 29156017)
3. Hayashi Y, et al,. Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. Eur J Pharmacol 2000; 395: 217-224. (Pubitemid 30254371)
4. Liepinsh E, et al,. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J Cardiovasc Pharmacol 2006; 48: 314-319. (Pubitemid 46066837)
5. Bieber LL,. Carnitine. Annu Rev Biochem 1988; 57: 261-283.
6. Foster DW,. The role of the carnitine system in human metabolism. Ann NY Acad Sci 2004; 1033: 1-16. (Pubitemid 39656734)
7. Chapela SP, et al,. Involvement of L-carnitine in cellular metabolism: beyond Acyl-CoA transport. Mini Rev Med Chem 2009; 9: 1518-1526.
8. Indiveri C, et al,. The carnitine transporter network: interactions with drugs. Curr Chem Biol 2010; 4: 108-123.
9. Rebouche CJ,. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci 2004; 1033: 30-41. (Pubitemid 39656736)
10. Rebouche CJ,. Carnitine function and requirements during the life cycle. FASEB J 1992; 6: 3379-3386. (Pubitemid 23007103)
11. Dambrova M, et al,. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med 2002; 12: 275-279. (Pubitemid 35286766)
12. Liepinsh E, et al,. Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart. Life Sci 2008; 83: 613-619.
13. Degrace P, et al,. Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat. Mol Cell Biochem 2004; 258: 171-182. (Pubitemid 38268212)
14. Oppedisano F, et al,. Interaction of mildronate with the mitochondrial carnitine/acylcarnitine transport protein. J Biochem Mol Toxicol 2008; 22: 8-14. (Pubitemid 351360157)
15. Minkler PE, et al,. Strategy for the isolation, derivatization, chromatographic separation, and detection of carnitine and acylcarnitines. Anal Chem 2005; 77: 1448-1457. (Pubitemid 40327886)
16. Vernez L, et al,. Determination of carnitine and acylcarnitines in urine by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. J Chromatogr A 2003; 984: 203-213. (Pubitemid 35454085)
17. Vernez L, et al,. Determination of carnitine and acylcarnitines in plasma by high-performance liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 1233-1238. (Pubitemid 38702390)
18. Davis AT, et al,. Dietary mildronate supplementation has no effect on carnitine biosynthetic enzyme mRNA expression in rat. Nutr Res 2007; 27: 225-229. (Pubitemid 46566385)
19. Hirche F, et al,. Determination of carnitine, its short chain acyl esters and metabolic precursors trimethyllysine and gamma-butyrobetaine by quasi-solid phase extraction and MS/MS detection. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 2158-2162.
20. Vernez L, et al,. Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis. Nephrol Dial Transplant 2006; 21: 450-458. (Pubitemid 43160002)
21. Lv YF, et al,. Determination of mildronate in human plasma and urine by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 852: 35-39.
22. Peng Y, et al,. Determination of mildronate by LC-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 551-556.
23. Dambrova M, et al,. Effect of inhibiting carnitine biosynthesis on male rat sexual performance. Physiol Behav 2008; 95: 341-347.
24. Jaffe M,. Ueber die Niederschlag, welchen Pikrinsaure in normalem Ham erzeugt und uber eine neue Reaction des Kreatinins. Z physiol Chem 1886; 10: 391-400.
25. Calvani M, et al,. Carnitine replacement in end-stage renal disease and hemodialysis. Ann NY Acad Sci 2004; 1033: 52-66. (Pubitemid 39656738)
26. Rebouche CJ, Engel AG,. Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport. J Clin Invest 1984; 73: 857-867. (Pubitemid 14156870)
27. Stanley CA,. Carnitine deficiency disorders in children. Ann NY Acad Sci 2004; 1033: 42-51. (Pubitemid 39656737)
28. Liepinsh E, et al,. Effects of long-term mildronate treatment on cardiac and liver functions in rats. Basic Clin Pharmacol Toxicol 2009; 105: 387-394.
29. Grigat S, et al,. The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate. Drug Metab Dispos 2009; 37: 330-337.
30. Tars K, et al,. Crystal structure of human gamma-butyrobetaine hydroxylase. Biochem Biophys Res Commun 2010; 398: 634-639.
31. Grube M, et al,. Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 2006; 113: 1114-1122.
32. Longo N, et al,. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006; 142C: 77-85.
33. Cederblad G,. Plasma carnitine and body composition. Clin Chim Acta 1976; 67: 207-212.